ORAGENICS FILES ANNUAL REPORT ON FORM 10-K
Oragenics Inc. (OGEN)
NASDAQ:AMEX Investor Relations:
ir.oragenics.com
Company Research
Source: GlobeNewswire
REPORTS YEAR OF STRATEGIC TRANSFORMATION AND CLINCIAL ADVANCEMENT SARASOTA, Fla., March 17, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company pioneering brain-targeted therapeutics through proprietary intranasal delivery technology, today announced the filing of its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, with the U.S. Securities and Exchange Commission. In conjunction with this filing, the Company is providing a shareholder update on key operational and clinical milestones achieved during 2025 and progress made in the first quarter of 2026. The Annual Report on Form 10-K, including audited financial statements for the fiscal year ended December 31, 2025, is available on the SEC's EDGAR system at www.sec.gov and on the Company's investor relations website at www.ir.oragenics.com. 2025: A YEAR OF DECISIVE TRANSFORMATION Fiscal year 2025 represented a pivotal year in Oragenics evolution — from a c
Show less
Read more
Impact Snapshot
Event Time:
OGEN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OGEN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OGEN alerts
High impacting Oragenics Inc. news events
Weekly update
A roundup of the hottest topics
OGEN
News
- ORAGENICS FILES ANNUAL REPORT ON FORM 10-K [Yahoo! Finance]Yahoo! Finance
- PRISM BioLab partners with Receptor.AI for molecule discovery [Yahoo! Finance]Yahoo! Finance
- ORAGENICS INITIATES PHASE IIA CLINICAL TRIAL SITE ACTIVATION [Yahoo! Finance]Yahoo! Finance
- ORAGENICS INITIATES PHASE IIA CLINICAL TRIAL SITE ACTIVATIONGlobeNewswire
- ORAGENICS EXPLORES EXPANSION OF CNS PLATFORM PURSUING ACQUISTION OF ASSETS IN BRAIN HEALTH, RECOVERY, AND NEUROPROTECTION [Yahoo! Finance]Yahoo! Finance
OGEN
Sec Filings
- 3/16/26 - Form 10-K
- 3/11/26 - Form 8-K
- 1/22/26 - Form S-3
- OGEN's page on the SEC website